Deferasirox for managing iron overload in people with myelodysplastic syndrome

Abstract

BACKGROUND: The myelodysplastic syndrome (MDS) comprises a diverse group of haematopoietic stem cell disorders. Due to symptomatic anaemia most patients require supportive therapy including repeated red blood cell (RBC) transfusions. In combination with increased iron absorption, this contributes to the accumulation of iron resulting in secondary iron overload and the risk of organ dysfunction and reduced life expectancy. Since the human body has no natural means of getting rid of excess iron, iron chelation therapy is usually recommended. However, whether the new oral chelator deferasirox leads to relevant benefit is unclear.OBJECTIVES: To assess the effectiveness and safety of oral deferasirox in people with myelodysplastic syndrome and iron overload.SEARCH STRATEGY: We searched MEDLINE, EMBASE, The Cochrane Library, Biosis Previews, Web of Science, Derwent Drug File, XTOXLINE and three trial registries: Current Controlled Trials: www.controlled-trials.com, ClinicalTrials.gov: www.clinicaltrials.gov, ICTRP: www.who.int./ictrp/en/. Most recent searches of these databases: June 2010.SELECTION CRITERIA: Randomised controlled trials comparing deferasirox with no therapy/placebo or with another iron chelating treatment schedule.DATA COLLECTION AND ANALYSIS: No studies eligible for inclusion in this review were identified.MAIN RESULTS: No studies were included in this review. However, we identified one ongoing study comparing deferasirox with deferoxamine.AUTHORS' CONCLUSIONS: We planned to report evidence from randomised clinical trials evaluating the effectiveness of deferasirox compared to either placebo/no treatment or other chelating regimens such as deferoxamine in people with myelodysplastic syndrome. However, no completed randomised trials addressing this question could be identified.One ongoing randomised study comparing deferasirox with placebo was identified and preliminary data will hopefully be available soon. These results will be important to inform physicians and patients on the advantages and disadvantages of this treatment option. Registry Number/Name of Substance 0 (Benzoates). 0 (Iron Chelating Agents). 0 (Triazoles). 0 (deferasirox). ISSN Electronic 1469-493X ISSN Linking 1361-6137 Digital Object Identifier http://dx.doi.org/10.1002/14651858.CD007461.pub2